US originators preparing an EU launch have, for decades, treated launch sequencing as a commercial decision calibrated against the same exclusivity rules they deal with at home: Hatch-Waxman's five-year new-chemical-entity and three-year new-clinical-investigation exclusivities, the Medicare Part D negotiation cycle, and now the Inflation Reduction Act's selected-drug eligibility clock. The EU has run on a parallel logic. The relevant inputs at the EU launch table were familiar: which Member States offered first-cycle pricing premia, which would reference the others downward, which had public-procurement systems that compressed margins, which were small enough to skip without strategic cost. Industry data, including IQVIA's annual W.A.I.T. Indicator survey published for the European Federation of Pharmaceutical Industries and Associations, indicate that newly authorized medicines reach their last EU Member State substantially later than their first, with the gap varying materially by therapeutic area and period. The EU Pharma Package final compromise text published on 6 March 2026 does not abolish that asymmetry, but it changes its price. Art. 56a of the new Directive gives any Member State a formal mechanism to demand launch, and Art. 56a(5) of the Directive terminates the EU regulatory market protection in that Member State if supply does not follow within three years. A US-headquartered originator whose internal launch decisions have followed the Medicare-and-major-markets logic of the IRA has to count the cost of every Member State it skips.
1. The Mechanism: How a Member State Launch Request Operates Under Art. 56a of the Directive
Art. 56a of the Directive sits inside the chapter dealing with the obligations of the MAH and operates as a conditional overlay on the regulatory protection regime in Art. 80 and Art. 81 of the Directive. Its first paragraph is explicit on its scope: it applies to a medicinal product covered by a valid marketing authorization in the territory of a Member State that is subject to regulatory protection under Art. 80 of the Directive or, if applicable, to orphan market exclusivity under Art. 72 of the Regulation. Within that window, the Member State may request the holder to place the product on its market and to supply it so that the needs of patients in that Member State are covered as specified by the Member State.1Final compromise text for a Directive on the Union code relating to medicinal products for human use, ST-6367/26 (24 February 2026, confirmed by Coreper on 6 March 2026), Art. 56a. Paragraph 2 then specifies what the Member State may require the holder to do: submit a valid pricing and reimbursement application under national law, fulfill specific requirements in procurement procedures, or establish a roll-out plan agreed with that Member State, with the arrangements to implement those requirements being proportionate to the objective pursued and in compliance with Union law. Where the regulatory protection window has expired, the Member State retains the national pricing, procurement and supply tools it has always had; Art. 56a of the Directive itself, however, no longer engages.
The Member State must communicate its request within one year from the marketing authorization, with explicit reference to Art. 56a of the Directive, and the holder and the Member State are then required to cooperate in good faith and to undertake best efforts, within the limits of their respective responsibilities, to ensure availability and supply. The roll-out plan itself is jointly drafted: the holder prepares it and the Member State agrees it, with either party able to require updates where developments such as evolving demand or changes in manufacturing or distribution capacity make the original plan obsolete. The drafting is deliberately bilateral, and the recital framing in the new Directive's recital (53b) makes clear that the Member State is not being given a unilateral pricing or volume-setting power. What it is given is the legal handle to put the holder under a defined, time-limited supply obligation with a regulatory consequence attached.
Art. 56a of the Directive converts the historical EU asymmetry of patient access into a conditional regulatory exclusivity: every Member State a US originator deliberately skips becomes a candidate for a request-driven loss of regulatory market protection in that territory three years after the request.
Art. 56a of the Directive has its bite because it sits inside the regulatory-protection regime rather than alongside it. Art. 80 and Art. 81 of the Directive establish an eight-year regulatory data protection period followed by a one-year market-protection period. That year can be extended by 12 months for unmet medical need, for comparator trials filed in the Union first or within 90 days, or for multi-Member-State trials; these extensions are alternatives in practice, because market protection is capped at two years in total. A further year can be added where a new therapeutic indication that brings significant clinical benefit is authorized during the data-protection period, for up to three years of market protection in all.2ST-6367/26 (n 1), Art. 80(1)–(2) and Art. 81(2)–(2b) (8+1 baseline plus conditional extensions). Art. 56a(5) of the Directive does not touch the data-protection period; it disapplies, in the requesting Member State only, the market-protection period in Art. 80(2) of the Directive and any prolongation of that period under Art. 81 of the Directive. The intervention is narrow, but the value at stake can be large: in indications where generic or biosimilar entry shifts revenue materially, one lost year of market protection in a Member State is the difference between an extra year of branded sales and an extra year of erosion.
The Regulation-Side Parallel
For centrally authorized products, the configuration that dominates the US-originator portfolio, Art. 5a of the Regulation establishes a parallel obligation to supply at Union level. Its scope is, in one important respect, wider than that of Art. 56a of the Directive: it reaches products subject not only to regulatory protection under Art. 80 of the Directive or orphan exclusivity under Art. 72 of the Regulation, but also to patent or supplementary protection certificate, typically a materially longer window for a US-originator blockbuster. Within that wider scope a Member State may either pursue the route of Art. 56a of the Directive or proceed independently under Art. 5a of the Regulation; the same narrowly drawn force-majeure carve-out applies in identical wording, with recital (11a) of the Regulation adding a further Article-5a-specific saving consideration providing that the obligation should not compromise the financial viability of the company.
The procedural consequence, however, differs structurally from Art. 56a(5) of the Directive. Art. 5a(2) of the Regulation opens a Commission-escalation route gated by a four-week holder-observation window; paragraph 3 requires the Commission, where more than one Member State invokes paragraph 2 against the same product, to bring the holder into good-faith negotiations; paragraph 4 requires the Commission to report four years after the date of application on whether legislative proposals are needed to introduce penalties under Art. 172 of the Regulation. Those penalties (Commission-imposed fines up to 5% of the holder's Union turnover in the preceding business year, plus periodic penalty payments up to 2.5% of average daily Union turnover) apply only to the obligations enumerated in Annex II of the Regulation, and Art. 5a of the Regulation is not among them. Until the Commission's four-year report becomes a legislative vehicle that adds Art. 5a of the Regulation to its Annex II, the immediate teeth of Art. 5a of the Regulation are the Commission-dialogue track, not a financial-penalty track. The contrast with Art. 56a(5) of the Directive is therefore structural rather than incremental: Art. 56a of the Directive delivers a self-executing regulatory consequence at the three-year mark; Art. 5a of the Regulation delivers a Commission-supervised compliance dialogue whose financial-penalty teeth depend on future legislative action.3ST-6367/26 (n 1), Art. 56a(5)–(6); Reg ST-6366/26, Art. 5a, Art. 72(2), Art. 172 + Annex II, recital (11a).
The transitional rules are correspondingly narrow. Art. 219(1a) of the Directive allows Member States to begin applying Art. 56a of the Directive from twelve months after entry into force, but only in respect of products authorized after entry into force; products already on the EU market on the relevant date are insulated. A second subparagraph addresses the interim window between entry into force and date of application: for products authorized under Regulation 726/2004 or Directive 2001/83 during that period, a requesting Member State that has not received supply may disapply the second subparagraph of Art. 10(1) of the old Directive (the ten-year market-protection rule under the legacy 8+2(+1) regime), accelerating generic or biosimilar entry into the requesting Member State by up to two years, or up to three where the +1 significant-clinical-benefit extension would otherwise have applied.
2. The Three-Year Clock and Loss of Market Protection in That Territory
Art. 56a(5) of the Directive sets out the consequence in operational terms. Where, within three years after a Member State submitted its request under paragraph 2, the holder has not, within the limits of its responsibilities, made the medicinal product available and has not supplied it continuously within that period so that the needs of patients in the requesting Member State are covered, the market protection under Art. 80(2) of the Directive and any prolongation of market exclusivity for orphans under Art. 72(2) of the Regulation do not apply within that Member State, and Art. 166(5) of the Directive applies. The three-year clock therefore runs not from authorization, not from refusal of a pricing application, and not from any failure of negotiation in isolation, but from the date of the Member State's formal request under paragraph 2. The starting gun is procedural; the consequence at the finish is substantive.
The three-year mechanism has two features. The first is that the consequence is geographically partitioned. Loss of market protection applies only in the requesting Member State; the holder's protection elsewhere in the Union is undisturbed. The second is that the consequence is asymmetric in time. The data-protection period in Art. 80(1) of the Directive continues to bar a generic or biosimilar applicant from relying on the originator's pre-clinical and clinical data for the standard period. What lapses is the further market-protection year (and any extensions of it under Art. 81 of the Directive). Art. 56a(6) of the Directive goes further by accelerating the procedural runway for that generic or biosimilar entrant: where a Member State has made the information about a lapse publicly available under paragraph 5a, a generic or biosimilar application referring to that reference product may be validated and assessed by the national competent authority or the European Medicines Agency from six years after the start of the data-protection period of the reference medicinal product, even though the marketing authorization itself may not be granted prior to the expiry of the regulatory data-protection period. In practice, the generic applicant can begin the regulatory assessment process up to two years before the originator's data-protection period expires, with an authorization issuing on day one of the now-stripped market-protection window; generic entry comes earlier both because the year of market protection is lost and because the applicant is ready to enter on its first day. That procedural acceleration is reinforced by the parallel widening of the Bolar exemption elsewhere in the new framework, which allows the generic applicant to prepare pricing, reimbursement, and tender-submission steps without infringement risk during the same window.
For an originator whose European pricing model assumed eight-plus-one or eight-plus-one-plus-one years of exclusivity in every Member State, the lapse has a direct cost. The Pharma Package compromise kept a one-year baseline market protection because, in many indications, that final year is the originator's last year of full margins before biosimilar or generic competition erodes them. Stripping it in a single Member State opens a recognized first-mover window for a generic competitor in that territory and accelerates the cross-border price-reference signal to higher-price markets that have launched on time. Because Art. 56a(5) of the Directive reaches only the regulatory market-protection period, the lapse accelerates generic or biosimilar entry only where patent and supplementary protection certificate cover have already fallen away in the Member State concerned: for a product still shielded by a patent or supplementary protection certificate when the market-protection year would otherwise run, the stripped year changes nothing the originator can monetize, and the sanction costs most for products whose regulatory market protection is the last barrier to entry. On the orphan side the consequence runs through Art. 72(2) of the Regulation: Art. 56a(5) of the Directive reaches the prolongation of orphan market exclusivity, so a US rare-disease originator can lose those additional twelve-month increments, grantable up to twice for new orphan indications and stacked on top of the nine- or eleven-year base exclusivity, in a Member State whose request it did not, or could not, satisfy. The revenue the originator stands to lose depends on the indication's value in the affected Member State, the length of any extension under Art. 81 of the Directive or orphan prolongation that would otherwise have applied, and how quickly a generic or biosimilar competitor enters.
3. Defenses, Force Majeure, and Reimbursement-Deadlock Treatment
The defenses available to a holder facing the three-year clock are textually narrow. Art. 56a(8) of the Directive contains the carve-out: holders shall comply with the obligations set out in Art. 56a of the Directive, except for exceptional and unforeseeable circumstances, including those related to disruptions of supply, or duly justified circumstances fully outside the holder's control, the consequences of which could not have been avoided even if all best and reasonable measures had been taken; the holder must provide an explanation of the case and circumstances and justify the reasons for non-compliance. The drafting follows EU force-majeure case-law without reproducing it verbatim, and three features stand out. The carve-out is built from two alternative limbs: the first reaching exceptional and unforeseeable circumstances (expressly including supply disruptions), the second duly justified circumstances fully outside the holder's control and unavoidable despite all best and reasonable measures. Each limb is internally cumulative, but a holder need satisfy only one, and both set a demanding threshold. The carve-out's reference to disruptions of supply tracks the shortages framework of Chapter X of the Regulation rather than introducing an independent supply-failure defense. And the burden of proof, by the textual logic of the saving clause, sits on the holder.
The defenses the text does not mention are at least as important as the one it does. The recital framing in recital (53a) of the Directive describes the policy rationale, namely that practice shows the placing on the market of authorized medicinal products does not occur, is delayed, or occurs in quantities that do not correspond to the needs of those Member States; but the recital does not translate that framing into a textual defense of good-faith pricing-and-reimbursement deadlock. A holder that has submitted a valid pricing application under Art. 56a(2)(a) of the Directive within the agreed roll-out plan, that has engaged the national pricing authority in good faith, and that has nonetheless failed to reach agreement within the three-year window is not on its face protected by paragraph 8: a pricing disagreement is neither an exceptional and unforeseeable circumstance nor one fully outside the holder's control. Given the absence of any textual reference to pricing or reimbursement disagreements in Art. 56a(8) of the Directive and the narrowly drawn, EU-force-majeure-inspired wording of both limbs, it is at best uncertain whether a reimbursement deadlock that is not attributable to the holder, particularly where the Member State has shifted its pricing benchmark mid-procedure or has refused to commence the procedure at all, would qualify; this is the area in which early national case-law and possible preliminary references to the Court of Justice will be pivotal.
The loss of market protection is the automatic legal consequence of the factual situation described in Art. 56a(5) of the Directive; there is no separate Union-level declaration of non-compliance before the lapse takes effect, no hearing under Art. 56a of the Directive, no independent finding of non-compliance prior to the loss of market protection. The Member State's function under paragraph 5a is to notify and publicize that consequence and, for centrally authorized products, to notify the European Medicines Agency; it is recognition of the lapse, not creation of it. The Pharmaceutical Committee under paragraph 8 may exchange views on national measures envisaged in the event of non-compliance, but its function is consultative rather than adjudicative. The judicial route, where a holder seeks to contest a Member State's invocation of paragraph 5, runs through national administrative-law proceedings in the requesting Member State, with the prospect of Art. 267 TFEU referral to the Court of Justice on the interpretation of paragraph 8's saving clause. The temporal asymmetry that follows is structural: the lapse takes effect operationally before any court has ruled on whether the conditions for invoking it were satisfied. A holder that prevails in litigation three or four years later may recover damages, but the generic or biosimilar entrant whose application under Art. 56a(6) of the Directive was validated in the meantime has, by then, already entered the territory.
4. Coordination Risk: Can Member States Effectively Coordinate Requests?
The text of Art. 56a of the Directive is, with deliberate precision, a Member-State-by-Member-State mechanism. Each Member State acts in its own name, on its own timetable, with its own roll-out plan. There is no provision for a coordinated Union-level request, no joint-procedure path through any of the existing inter-Member-State regulatory coordination bodies, and no role for the Commission in initiating or sequencing requests. Paragraph 8 contemplates only that Member State representatives may request the Commission to discuss issues related to the practical application of the Article in the Pharmaceutical Committee established by Council Decision 75/320/EEC,4Council Decision 75/320/EEC of 20 May 1975 setting up a pharmaceutical committee [1975] OJ L147/23, as referenced in ST-6367/26 (n 1), Art. 56a(8). with bodies responsible for health technology assessment under Regulation (EU) 2021/2282 and national pricing-and-reimbursement bodies invitable to deliberations as required. The Pharmaceutical Committee's mandate, the Decision makes clear, is consultative; it does not transform into a coordinating organ by virtue of paragraph 8.
The structural consequence is that coordination, if it happens at all, will happen through the informal pricing-and-reimbursement networks that already exist outside the Pharma Package. Beneluxa, the cooperation among Belgium, the Netherlands, Luxembourg, Austria and Ireland on horizon scanning, health technology assessment and joint price negotiation, is the most institutionally developed of these; the Valletta Declaration network of southern European Member States and the Nordic Pharmaceutical Forum operate on parallel logics with different memberships. None of these networks has authority under Art. 56a of the Directive; none can issue a coordinated launch request that legally binds participating Member States to act in concert. What they can do, and what their pricing-cooperation work already shows they do, is exchange information on negotiating positions, on launch-timing patterns, and on holder behavior across markets. A coordinated wave of requests under Art. 56a of the Directive from Beneluxa members targeting the same product would not be a coordinated request in the legal sense, but it would be operationally indistinguishable from one for the holder on the receiving end.
The first-mover incentive that follows is asymmetric and, for the small or low-price Member State, attractive. A Member State acting alone bears the entire administrative cost of preparing the request, agreeing the roll-out plan, and monitoring compliance, but captures only its own share of the consequence: market protection lapses in its territory only, the generic or biosimilar window opens only there, and the price-reference signal to other Member States is a side effect rather than the primary objective. For a small Member State whose health system would otherwise wait years for the originator's voluntary launch, the calculus is plain: the cost of acting first is fixed, the benefit (supply, or else the lapse of market protection after three years) goes to that Member State, and a faster-moving peer is unlikely to undercut it, because every peer faces the same fixed cost. For a large Member State whose internal market the originator launches into on commercial logic anyway, the calculus is the reverse: the marginal benefit of a request under Art. 56a of the Directive is small, because the launch is already happening, and the administrative cost remains. The incentives therefore favor requests from the Member States that the originator's launch strategy has historically deprioritized.
5. Parallel Trade and the Originator's Bargaining Power in EU Pricing
The drafters of Art. 56a of the Directive anticipated that an originator under three-year pressure might launch into a low-price Member State at a concessionary price to stop the clock. Whether the strategy survives parallel trade is a separate question. The EU exhaustion doctrine in the medicines context, settled across the Court of Justice's Centrafarm, Bristol-Myers Squibb and Boehringer jurisprudence, treats a product placed on the market in one Member State with the holder's consent as exhausted for free-movement purposes; parallel exports from the lower-price Member State to higher-price Member States cannot be blocked on intellectual-property grounds alone.5Centrafarm (Case 15/74), Bristol-Myers Squibb v Paranova (Joined Cases C-427/93, C-428/93 and C-429/93) and Boehringer Ingelheim v Swingward (Case C-143/00): EU exhaustion and the repackaging of parallel-imported medicines. The Pharma Package does not disturb that baseline. What it adds, through Art. 166(5) of the new Directive, is an asymmetric carve-out: where market protection has lapsed in a Member State under Art. 56a(5) of the Directive, wholesale distributors and distance-selling operators are barred from making the generic, biosimilar, hybrid or biohybrid medicinal product available on the market of another Member State where the protection still applies, during the period of that protection.6ST-6367/26 (n 1), Art. 56a(5a) and Art. 166(5) (asymmetric wholesale-distribution carve-out: bars generic export from lapsed-protection MS into protection-intact MS). Wholesalers must keep specific records for three years where the product is intended for export to another Member State in which protection periods do not apply pursuant to Art. 56a(5) of the Directive.
The carve-out is one-directional and constrains only the generic side. The originator's own product, launched in the low-price Member State to defeat the request, remains subject to ordinary free-movement rules; parallel exporters can buy it at the lower price and resell it into a higher-price Member State without a barrier under Art. 166(5) of the Directive. The economic effect follows from that one-way design. An originator that gives in to a Member State request by launching at a concessionary price opens a parallel-trade channel that erodes its prices in the higher-price Member States that launched on time, and those Member States already had more bargaining power than the requesting Member State. The parallel-import logic, and its consequences under Swiss and EU exhaustion law, are set out in more detail in the analysis of parallel imports under pharma distribution agreements.
The effect on pricing negotiations across the EU matters more than the direct loss of revenue. An originator's bargaining power in pricing negotiations with high-price Member States has historically rested on two credible threats: to skip lower-price Member States that would otherwise reference downward, and to withdraw where the offered price was unattractive. Art. 56a of the Directive weakens the first of these by attaching a cost to the skip, and the second by attaching a cost to what amounts to a withdrawal: failing to supply for three years after a request. The remaining originator response, launching everywhere at a defensible price, moves toward the availability-in-all-Member-States objective that the policy framing in recital (45) and recital (53a) of the Directive sets out, even as those recitals leave pricing and reimbursement to Member-State competence. Whether US originators whose internal pricing committees were calibrated on Medicare Part D and the IRA's negotiation framework can absorb that EU-wide price-discipline shift without re-pricing their global launch model is, for now, unresolved.
6. Strategic Considerations: Selective Launch, Pricing Sequencing, and the Swiss Reference
Several unresolved questions follow from Art. 56a of the Directive. The first is whether a US originator still has a credible skip-this-country threat that Member States believe. The pre-Pharma-Package version of the threat rested on the simple proposition that the originator could decline to file a pricing application, or could withdraw if the price offered was unattractive, with no further consequence than lost revenue in that market. Under the new rules the threat survives, but only as a conditional one. A Member State that has not exercised its authority under Art. 56a of the Directive leaves the historical posture intact, and small Member States with limited administrative capacity may, for reasons unrelated to the originator's product, decline to invoke the mechanism at all. But the credibility of the threat now turns on a Member-State-specific judgment about which Member States are likely to act, on what timetable, and how a request that the originator concedes to mid-three-year-window will be valued against a request the originator contests to the end. The threat rests instead on a separate judgment for each Member State, and the originator's regulatory affairs and commercial functions are not used to making those judgments together.
A related and structurally harder question is whether early launch at a low reference price in one Member State, undertaken to defeat a request under Art. 56a of the Directive, damages EU-wide pricing more than the regulatory exclusivity it preserves. The arithmetic turns on variables the Pharma Package does not fix: the scope for parallel trade, reference-pricing cascades, indication-specific generic or biosimilar entry speed, and the breadth of the parallel-trade-permissive distributor network in the affected Member State. The non-orthodox component is that the answer depends on facts the originator's pricing committee has not historically priced together. The reference-pricing effect of a Member State that the originator's reference-pricing model has so far left out, because no launch occurred there, is unmeasured. The parallel-export potential of a distributor footprint built up to serve, rather than evade, the originator's launch decisions is unquantified. And the substitution effect of a generic or biosimilar entrant whose window under Art. 56a(6) of the Directive opens six years after data-protection commencement, rather than at the standard regulatory-protection horizon, has no historical comparator to calibrate against.
The Swiss Reference-Pricing Question
Switzerland is a third country to the EU for medicinal-product authorization, with Swissmedic authorizing independently of the EU procedures, and the textual scope of Art. 56a of the Directive is Member State only; the mechanism does not give Swissmedic a parallel authority over a holder's Swiss launch decisions, and the Swiss authorization framework under the HMG remains structurally distinct from the centralized and decentralized procedures the Pharma Package amends. Whether Swiss pricing becomes a sequencing tool in the EU context is therefore a question of cross-border reference pricing rather than of EU regulatory law. The directional logic favors Swiss-first sequencing where the originator seeks a high-price reference anchor outside the reach of Art. 56a of the Directive, but that very sequencing already drew regulatory and political scrutiny in the Swiss three-year reference-price review, which the analysis of Swiss pharma pricing under the three-year review covers. Whether a Swiss-first sequence remains tactically attractive once EU Member States internalize it as a signal of the originator's pricing position is a question the new rules leave open.
The Inflation Reduction Act Overlay
The US-originator-specific overlay turns on the Inflation Reduction Act's price-negotiation timing and the US launch-first norm. The IRA's Medicare drug-price-negotiation framework turns on the time elapsed since FDA approval. A small-molecule drug can be selected for negotiation once seven years have passed since FDA approval, and a biologic once eleven years have passed since licensure; the negotiated price takes effect about two years after selection. For a product first approved only for designated rare-disease indications, the years run from the day it leaves the orphan exclusion. US originators are increasingly designing launch-and-pricing strategies with that clock in mind, even where the empirical record of how originator behavior has actually shifted in response remains thin.7Inflation Reduction Act of 2022, Pub L No 117-169, §§ 11001–11003, 136 Stat 1818, as amended by Pub L No 119-21, § 71203, 139 Stat 72, 320–21 (2025) (codified principally at 42 USC §§ 1320f to 1320f-7). The intersection with Art. 56a of the Directive is unstable in two respects. The US launch-first norm means that the EU launch falls into the window that Art. 56a of the Directive measures from the European authorization date, with the result that an EU pricing-negotiation cycle compressed by Art. 56a of the Directive may collide with a US pricing decision that the originator is simultaneously making under IRA-eligibility logic. The directional consequence is that a price set in a low-price Member State to defeat a request under Art. 56a of the Directive, then propagated through the EU's reference-pricing cascade into Germany, the Netherlands, the Nordic countries and beyond, becomes a data point that the IRA negotiation will see when the US negotiation window opens. Whether the originator's US pricing can absorb a globally lower EU reference price as the cost of avoiding the lapse under Art. 56a of the Directive, or whether the IRA forces a different launch sequence that accepts the lapse under Art. 56a of the Directive to protect the US price, is a question that no single function inside a US originator is placed to answer.
The deepest question Art. 56a of the Directive raises, on the analysis offered here, is whether the mechanism inadvertently re-prices the centralized marketing authorization itself. The pre-Pharma-Package centralized authorization conferred a right to place the product on the Union market that the originator could exercise or not exercise at its discretion; the regulatory protection period that attached to it ran by operation of law from the authorization date and did not depend on the originator's launch decisions in any particular Member State. Art. 56a of the Directive converts that absolute right into a contingent one: in every Member State that exercises its paragraph 1 authority, the regulatory protection becomes contingent on a supply outcome the originator can be required to deliver on a roll-out plan it has agreed under regulatory pressure. The contingency is limited, applying only Member State by Member State and only to the market-protection period, not the data-protection period, but it is real. Whether the centralized authorization, going forward, is best understood as a Union-wide commercial right with conditional exclusivity carve-outs in particular Member States, or as a bundle of Member-State-specific conditional rights tied together by a single regulatory dossier, is itself a characterization question. The answer matters: it affects how the right is valued in M&A diligence, how it is treated in licensing agreements, and how it is described to investors. The Directive itself recognizes that the mechanism is experimental: Art. 216(1) of the Directive requires the Commission, approximately a decade after the new framework's date of application, to report to the European Parliament and the Council on the application of the access-facilitating provisions in Art. 56a of the Directive, including whether they have in practice delivered timely availability and continuous supply in the Member States that have applied them, with the possibility of further legislative change in light of that experience.